QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
QQQ   304.39 (-0.58%)
AAPL   152.20 (-1.49%)
MSFT   256.51 (-0.71%)
META   187.48 (+0.51%)
GOOGL   103.34 (-1.37%)
AMZN   102.69 (-0.68%)
TSLA   195.16 (+2.73%)
NVDA   212.10 (+0.52%)
NIO   10.90 (-2.59%)
BABA   105.86 (-0.44%)
AMD   83.83 (-2.63%)
T   19.61 (-1.11%)
F   13.10 (-0.98%)
MU   59.95 (-3.94%)
CGC   2.95 (+1.03%)
GE   82.17 (+0.26%)
DIS   109.60 (-1.00%)
AMC   6.62 (+8.88%)
PFE   43.89 (-0.39%)
PYPL   83.10 (-2.83%)
NFLX   364.70 (-0.33%)
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$787.61
+4.48 (+0.57%)
(As of 02/6/2023 02:15 PM ET)
Add
Compare
Today's Range
$781.18
▼
$800.48
50-Day Range
$680.49
▼
$783.13
52-Week Range
$538.01
▼
$800.48
Volume
660,923 shs
Average Volume
677,718 shs
Market Capitalization
$85.77 billion
P/E Ratio
20.60
Dividend Yield
N/A
Price Target
$798.65

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1.8% Upside
$799.09 Price Target
Short Interest
Healthy
1.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.85mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 35 Articles This Week
Insider Trading
Selling Shares
$13.34 M Sold Last Quarter
Proj. Earnings Growth
10.58%
From $36.78 to $40.67 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

55th out of 1,027 stocks

Pharmaceutical Preparations Industry

19th out of 500 stocks

See Top Rated MarketRank™ Stocks Here
REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

January 6, 2023 | marketbeat.com
Four Undervalued Healthcare Stocks for 2023 (REGN)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
February 6, 2023 | finance.yahoo.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript
February 6, 2023 | Investing Trends (Ad)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
February 6, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Issues Quarterly Earnings Results, Beats Estimates By $4.38 EPS
February 5, 2023 | americanbankingnews.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 1-Year High on Better-Than-Expected Earnings
February 4, 2023 | msn.com
Regeneron Pharmaceuticals' Revenue Slides, Still Tops Street Views as R&D Spending Picks Up
February 3, 2023 | markets.businessinsider.com
Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN)
February 3, 2023 | msn.com
Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat
February 6, 2023 | Investing Trends (Ad)
New "Vertical" Technology Solves Solar Power's Major Flaw
Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive...Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power.
February 3, 2023 | finance.yahoo.com
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
February 3, 2023 | markets.businessinsider.com
Regeneron Pharmaceuticals Q4 Profit Declines
February 3, 2023 | markets.businessinsider.com
Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14%
February 3, 2023 | reuters.com
Regeneron quarterly profit plunges as COVID drug sales dry up
February 3, 2023 | msn.com
Regeneron posts Q4 beat as COVID therapy offsets Eylea impact
February 3, 2023 | finance.yahoo.com
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
February 3, 2023 | ca.finance.yahoo.com
Regeneron profit beats estimates on Dupixent strength
February 3, 2023 | finance.yahoo.com
Regeneron stock rallies after profit and revenue beat expectations by wide margins
February 3, 2023 | finance.yahoo.com
UPDATE 2-Regeneron profit beats estimates on Dupixent strength
February 3, 2023 | finance.yahoo.com
Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment
February 3, 2023 | finance.yahoo.com
UPDATE 2-Sanofi forecasts moderate profit growth on Dupixent demand
February 2, 2023 | seekingalpha.com
All eyes on Regeneron Q4 results with focus on blockbusters Dupixent, Eylea
February 1, 2023 | finance.yahoo.com
Time to Buy Cigna or Regeneron Stock Before Earnings?
February 1, 2023 | benzinga.com
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
January 31, 2023 | marketwatch.com
Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day
January 31, 2023 | finance.yahoo.com
Regeneron (REGN) Stock Moves -0.86%: What You Should Know
January 30, 2023 | finance.yahoo.com
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023 | finance.yahoo.com
Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
2/03/2023
Today
2/06/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
CIK
872589
Web
www.regeneron.com
Phone
(914) 847-7000
Fax
914-347-2113
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$799.09
High Stock Price Forecast
$970.00
Low Stock Price Forecast
$625.00
Forecasted Upside/Downside
+1.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
21 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$38.24
Trailing P/E Ratio
20.60
Forward P/E Ratio
21.41
P/E Growth
2.37
Net Income
$4.34 billion
Net Margins
35.64%
Pretax Margin
39.92%
Return on Equity
22.87%
Return on Assets
17.54%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
6.68
Quick Ratio
5.96

Sales & Book Value

Annual Sales
$12.17 billion
Price / Sales
7.05
Cash Flow
$81.28 per share
Price / Cash Flow
9.69
Book Value
$208.11 per share
Price / Book
3.78

Miscellaneous

Outstanding Shares
108,900,000
Free Float
99,112,000
Market Cap
$85.77 billion
Optionable
Optionable
Beta
0.25

Social Links


Key Executives

  • Leonard S. SchleiferLeonard S. Schleifer
    Co-President, Chief Executive Officer & Director
  • George Damis YancopoulosGeorge Damis Yancopoulos
    Co-President, Director & Chief Scientific Officer
  • Patrice Gilooly
    Senior VP-Quality Assurance & Operations
  • Robert E. LandryRobert E. Landry
    Chief Financial Officer & Executive VP-Finance
  • Neil StahlNeil Stahl
    Executive VP-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REGN shares.
View REGN analyst ratings or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

21 brokerages have issued 1 year price objectives for Regeneron Pharmaceuticals' stock. Their REGN share price forecasts range from $625.00 to $970.00. On average, they expect the company's share price to reach $799.09 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for REGN or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 on January 1st, 2023. Since then, REGN stock has increased by 9.0% and is now trading at $786.54.
View the best growth stocks for 2023 here.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our REGN earnings forecast.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.18 by $4.38. The biopharmaceutical company earned $3.41 billion during the quarter, compared to analyst estimates of $3.11 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 22.87% and a net margin of 35.64%. The firm's revenue for the quarter was down 31.1% compared to the same quarter last year. During the same period in the previous year, the company earned $23.72 earnings per share.
Read the conference call transcript.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sustainable Growth Advisers LP (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), New York State Common Retirement Fund (0.17%), DekaBank Deutsche Girozentrale (0.16%), New York State Teachers Retirement System (0.11%) and Assenagon Asset Management S.A. (0.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $786.54.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $85.65 billion and generates $12.17 billion in revenue each year. The biopharmaceutical company earns $4.34 billion in net income (profit) each year or $38.24 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 2/6/2023 by MarketBeat.com Staff